generic drugs

11 Easy and Great Ways to Save Money in 2013

With the prospect of higher taxes and federal budget cuts looming on Dec. 31, here are 11 easy ways you can save money and/or put a few extra dollars back in your pocket in 2013.

What Not to Do When Filling a Prescription

Cold and flu season is upon us. Americans spend $400 million on prescription drugs to relieve the symptoms, according to one study, and some of them spend too much. DailyFinance's Laura Rowley looks at what not to do when filling a prescription.

The Financial Landscape: Big Pharma Wins; So Does Greece

It's a good day to be a drugmaker after two pro-business Supreme Court rulings favored the industry. And it's an even better day for those who are counting on the EU bailing out Greece. But the folks at Google may want to search for "defense lawyers" -- they may be seeing subpoenas shortly.

Pfizer Sells Capsugel: Will More Asset Sales Follow?

On Monday, Pfizer announced it would sell its Capsugel business to private-equity firm KKR for $2.375 billion. If the hints the drugmaker has been giving lately are true, the move could be the start of two years of major asset sales. Here's what's ahead for the world's biggest pharmaceutical company.

The Five Best-Performing Biotech Stocks of 2011 -- So Far

Pharmaceuticals are facing big patent cliff problems this year, but several biotechnology stocks have been doing quite well: Their biologic drugs command high prices, tend become blockbusters, and -- perhaps most important -- are in far less danger from generic competition. Here are the big winners so far.

Top-Selling Drugs About to Lose Patent Protection

The pharmaceutical industry is about to fall off a cliff -- a patent cliff. Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from companies' bottom lines. Here's a rundown:

The Best Deal Around: $4 Generics


Wal-Mart Stores Inc. expanded a $4 offer for some prescription generic drugs to 11 more states Thursday, including Oklahoma, in its plan to reach all 50 states by as early as January with the discount program.Many consumers have yet to take advantage of the low prices for prescription drugs offered by many retailers. For example, some American consumers...

Sanofi-Aventis, Genzyme on the Brink of a Merger

It seems that months of merger talks between French pharmaceutical company Sanofi-Aventis and U.S. biotech Genzyme have entered the home stretch. This week, Sanofi is expected to offer $74 per share for the rare disease drugmaker, with an option included potentially worth $5 to $6 a share.

Pfizer Joins Other Pharmas in Giving a Cautious Outlook

Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:

A Depressing Outlook for Big Pharma's Next Few Years

After several years of robust expansion, the leading branded pharma companies will see growth slow to just 1.3% from now to 2015, independent market analyst company Datamonitor said in a new report. The primary culprit: expiring patents and an onslaught of generic competition.

Pharma News Briefs: Human Genome, Merck, Novartis

Here's a roundup of some of Wednesday's major pharmaceutical news: An FDA panel gave Human Genome Sciences a boost with a thumbs-up for its lupus drug, Benlysta; Merck's experimental heart drug appears to work well without side effects; and Novartis announced its plans for long-term growth.

How to Approve 'Biosimilar' Drugs? The FDA Has to Figure That Out

Unlike generics, which are the exact chemical copies of a brand-name drug, biosimilars have large and often complex proteins that are made in living cells, and tiny differences can play havoc with the product. It may take years for the FDA to create an approval process.

Sanofi-Aventis Inks 10-Year R&D Deal with Covance

French pharmaceutical company Sanofi-Aventis announced a 10-year agreement with Covance on Thursday under which the Princeton, N.J.-based contract research firm will provide it with drug development services. Sanofi-Aventis will pay Covance between $1.2 billion to $2.2 billion.

Endo to Acquire Generics Company Qualitest for $1.2 Billion

Endo Pharmaceuticals (ENDP) agreed to buy generics company Qualitest Pharmaceuticals for $1.2 billion cash. Qualitest is the sixth-largest U.S. generics company as measured by prescriptions filled. Qualitest will add about $400 million to Endo%u2019s annual revenue and 40 cents per share in annual adjusted earnings, Endo said in a statement.

Legal Briefing: Blog Was Violent Threat, Not Free Speech

In a case that tested the bounds of the First Amendment, Hal Turner, a right-wing radio shock jock, was convicted of threatening three judges' lives in his blog post. Plus, Eli Lilly loses a patent case for ADHD drug Strattera.

10 products to always buy generic

The main reason for buying generic products -- saving money -- is simple enough. But there's also the satisfaction of not giving in to the marketing...

AstraZeneca Stock Jumps After Court Ruling on Crestor

AstraZeneca shares surged by almost 9% Tuesday after the company scored a win in court regarding the patent for its cholesterol treatment, Crestor. The ruling means that AstraZeneca won't have to worry about generic competition for its multibillion-dollar statin until 2016.

Legal Briefing: Generic Pharmas on the Hook for Drug Safety

An FDA "bioequivalent" certification doesn't exempt generic drugmakers from responsibility for their medication's safety, a judge has ruled. Teva Pharmaceuticals had been sued for the problems its version of antidepressant Wellbutrin has caused users.